Study of EVO756 in Adults With Migraine
Key facts
- Where
- Québec, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07616128, who can take part
Where in Canada
- Centre de Recherche St-LouisQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Evommune, Inc.
- Trial code
- NCT07616128
- Record updated
- 4 November 2026
- Original description
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Inclusion: Adults aged 18 to <65 years; Migraine with or without aura, per ICHD-3 criteria; History of failure with prior preventive migraine treatments; Not currently using migraine preventive therapy.
Exclusion: Use of certain medications; Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders; Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities.